Cite
HARVARD Citation
Mateos, M. et al. (2022). Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. European journal of cancer. pp. 243-250. [Online].